RxDoctor Payments Data

Benjamin Remo, MD

Clinical Cardiac Electrophysiology · Easton, MDNPI 1376785717

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (39.7%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Boston Scientific at 51.5% of the total. 2025 is the largest year on record at $8,402, 4.1 times the $2,044 reported in 2019.

$19,860in general payments, 2019–2025

Across 180 payments — averaging $110.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$10K
  • Medtronic$5K
  • Abbott$3K
  • Biosense Webster, Inc.$534
  • Medical Device Business Services, Inc.$249
  • Irhythm Technologies, Inc.$133
  • plus $421 from 12 others

What the payments were for

  • Speaking & faculty fees$5,00025%
  • Travel & lodging$6,94635%
  • Food & beverage$7,88640%
  • Education$280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,860 in reported general payments places this provider in the 60th percentile of 63 clinical cardiac electrophysiology providers in Maryland.

See all clinical cardiac electrophysiology providers in Maryland

Medicare billing

Part B allowed, 2024
$191,070
Medicare patients
1,694
Services billed
3,040

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban400$470,619
XareltoRivaroxaban107$132,316
EntrestoSacubitril/Valsartan74$93,349
FarxigaDapagliflozin Propanediol41$44,493
Metoprolol Succinate607$9,858
Flecainide Acetate182$6,237
Diltiazem 24hr Er (Cd)Diltiazem Hcl95$3,620
Dofetilide22$1,997
Levalbuterol Tartrate HfaLevalbuterol Tartrate40$1,959
Atorvastatin Calcium126$1,718
Rosuvastatin Calcium101$1,437
Carvedilol102$1,150
Amiodarone Hcl59$1,079
Lisinopril82$910
ClopidogrelClopidogrel Bisulfate49$868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$470,619400 claims
NovartisEntresto$16$93,34974 claims
AstraZenecaFarxiga$13$44,49341 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 63 clinical cardiac electrophysiology providers in Maryland.

Other clinical cardiac electrophysiology in Easton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →